{"title":"药物基因组学:定量评估生物技术的前景","authors":"E. Razvi","doi":"10.5172/IMPP.1998.1.5-6.10","DOIUrl":null,"url":null,"abstract":"SummaryThis article presents an overview of the valuation strategy constructed by the author, with assistance from former colleagues from Biotechnology Industry Research of Frost & Sullivan, for determining the inherent value of a given genomicsbased therapeutic category of technology. The methodology focuses upon future market opportunities (in prospective sales of pharmaceuticals) and their relevance in terms of current dollars invested in constructing these paradigms.","PeriodicalId":13564,"journal":{"name":"Innovation-management Policy & Practice","volume":"27 1","pages":"10-12"},"PeriodicalIF":0.0000,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Business of Pharmacogenomics: Assessing Biotechnology’s Promise in Quantitative Terms\",\"authors\":\"E. Razvi\",\"doi\":\"10.5172/IMPP.1998.1.5-6.10\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"SummaryThis article presents an overview of the valuation strategy constructed by the author, with assistance from former colleagues from Biotechnology Industry Research of Frost & Sullivan, for determining the inherent value of a given genomicsbased therapeutic category of technology. The methodology focuses upon future market opportunities (in prospective sales of pharmaceuticals) and their relevance in terms of current dollars invested in constructing these paradigms.\",\"PeriodicalId\":13564,\"journal\":{\"name\":\"Innovation-management Policy & Practice\",\"volume\":\"27 1\",\"pages\":\"10-12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1998-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Innovation-management Policy & Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5172/IMPP.1998.1.5-6.10\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovation-management Policy & Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5172/IMPP.1998.1.5-6.10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Business of Pharmacogenomics: Assessing Biotechnology’s Promise in Quantitative Terms
SummaryThis article presents an overview of the valuation strategy constructed by the author, with assistance from former colleagues from Biotechnology Industry Research of Frost & Sullivan, for determining the inherent value of a given genomicsbased therapeutic category of technology. The methodology focuses upon future market opportunities (in prospective sales of pharmaceuticals) and their relevance in terms of current dollars invested in constructing these paradigms.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
